Our mission is to develop novel medications with precision drug delivery systems to enhance efficacy and maximize safety of treatments for children and adults with vascular anomalies. Our lead product candidate, ARK001, has the potential to be the first FDA-approved non-systemic topical (applied to the skin) treatment for infantile hemangioma (IH). ARK001 has the potential to change the approach to care for IH, allowing pediatricians and dermatologists to treat before the IH requires systemic therapy.